Roivant Sciences Ltd. Common Shares
ROIV
Closed
$37.75
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Key stats
Open
$36.36
Volume
5.40M
Market cap
$25.96B
Prev. close
$36.81
Impl / hst vl
-
Open interest
$0.00
$36.09
Day’s Range
$37.79
$20.78
52W Range
$36.63
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
3,142.67
P/B
5.73
Current ratio
18.37
Debt / Equity
-0.31
ROE
-6.85%
Gross margin
87.30%
Income growth
-213.95%
FCF growth
-13.82
Analysts estimates
Consensus rating
Buy
The average rating from top 9 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$39.36
The top 14 analysts forecasts that 12-month price may increase by 4.27%, with a low of $31.82 and a high of $47.25
$31.82
Low
$39.36
Avg
$47.25
High
Current price
Earnings
Q1 ‘26 revenue
$2.52M
Q1 ‘26 net income
$302.99M
Revenue
Net income
Previous EPS
-$0.17
Estimate EPS
-$0.32
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply